Aro Biotherapeutics is a biotechnology company based in Philadelphia, pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is focused on developing a pipeline of Centyrin-based therapeutic candidates and working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Aro Biotherapeutics

Unlocking the Potential of Genetic Medicines

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Johnson & Johnson Robotics and Digital Solutions

Ridgeback Capital

BioMotiv

Biotechnology Value Fund

BVF Partners

HealthCap

Ionis Pharmaceuticals

Northpond Ventures

Cowen Healthcare Investments

Johnson & Johnson Innovation – JJDC

We are excited for the opportunity to present at the 20th Annual WORLD Symposium 2024 meeting!

We are excited to announce we have secured our Series B financing!

https://lnkd.in/d_znquZc

We are excited to announce our transition to a clinical stage company with the start of our first in human trial of ABX1100, a Centyrin-siRNA conjugate in development for Pompe Disease

#Centyrin #siRNA #PompeDisease #RareDisease

https://lnkd.in/erdkqrKz

COM:AROBIOTX

Aro Biotherapeutics